Indivior (NASDAQ:INDV) Hits New 12-Month High – Here’s Why

Shares of Indivior PLC (NASDAQ:INDV) hit a new 52-week high on Tuesday . The company traded as high as $33.62 and last traded at $32.98, with a volume of 2062189 shares changing hands. The stock had previously closed at $32.75.

Wall Street Analysts Forecast Growth

INDV has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and set a $41.00 price objective (up from $27.00) on shares of Indivior in a research note on Friday, October 31st. Craig Hallum reaffirmed a “buy” rating and set a $41.00 price target on shares of Indivior in a research report on Friday, October 31st. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 3rd. HC Wainwright boosted their price objective on Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $32.17.

Indivior Price Performance

The firm has a market capitalization of $4.62 billion, a PE ratio of 54.00 and a beta of 0.68. The stock has a 50-day moving average price of $26.98 and a 200-day moving average price of $20.85.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%.The firm had revenue of $314.00 million during the quarter, compared to the consensus estimate of $257.66 million. Indivior has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Institutional Trading of Indivior

A number of hedge funds and other institutional investors have recently made changes to their positions in INDV. CWM LLC bought a new position in Indivior during the 3rd quarter valued at $25,000. Quarry LP acquired a new stake in shares of Indivior in the 3rd quarter valued at about $26,000. Raymond James Financial Inc. bought a new position in shares of Indivior during the second quarter worth about $26,000. Plato Investment Management Ltd acquired a new position in Indivior in the third quarter worth about $52,000. Finally, Amalgamated Bank bought a new stake in Indivior in the second quarter valued at about $61,000. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.